Flamingo Pharma UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
Similar Posts
MHRA approves tisotumab vedotin for the treatment of cervical cancer
As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
MHRA approves adrenaline nasal spray – the first needle-free emergency treatment for anaphylaxis in the UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
MHRA Safety Roundup: November 2025
Summary of the latest safety advice for medicines and medical device users
Guidance: Updates to CIR 520/2012 – Information for UK Marketing Authorisation Holders
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Clinical trials for medicines: labelling
Guidance on labelling for medicinal products used in clinical trials.
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors
As with any medicine, the MHRA will keep the safety and effectiveness of concizumab under close review.